Rheohaemapheresis in the treatment of nonvascular age-related macular degeneration

Bláha, M.; Rencová, E; Langrová, H; Studnička, Jan; Bláha, V.; Rozsíval, P; Lánska, M.; Sobótka, L.

doi:10.1016/j.atherosclerosissup.2012.10.023

Cited by 23 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Until now, there have been no effective pharmacological therapies for the dry form of AMD that have been documented by multicentre, randomised, double-blind studies 8,22 .…”

Section: Discussionmentioning

confidence: 99%

“…Bláha et al observed, after rheohaemapheresis (RH), not only absorption of soft drusen but also a reduction in or complete disappearance of drusenoid retinal pigment epithelium detachments (RPEDs). RH influenced rheological markers and most likely improved metabolism in the affected retinal areas, leading to the positive results 8 . RH results in a decrease in high-weight molecules, such fibrinogen, immunoglobulins (mainly IgM), LDL cholesterol and other compounds.…”

Section: Introductionmentioning

confidence: 99%

“…The non-exudative form involves a variety of presentations, including hard drusen, soft drusen, and geographic (areolar) atrophy of the retinal pigment epithelium (RPE). This non-exudative form of AMD accounts for 80-90% of AMD cases 5,8 . Greater intake of fish, nuts, and dark green, leafy vegetables has been associated with lower risk for AMD.…”

Section: Introductionmentioning

confidence: 99%

“…7 ). The Age-Related Eye Disease Study (AREDS), a multi-centre, randomised, controlled clinical trial, demonstrated that oral supplementation with a combination of vitamin C, vitamin E, β-carotene, zinc oxide and cupric oxide in patients with intermediate or advanced AMD in one eye resulted in a 25% relative risk reduction of developing advanced AMD in the other eye 5,8 . A comparison with placebo demonstrated a statistically significant odds reduction for the development of advanced AMD with antioxidants plus zinc 9 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Blood levels of antioxidants during age-related macular degeneration treatment by rheohaemapheresis

Aufartová¹,

Bláha²,

Kasalová³

et al. 2015

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Aims. Rheohaemapheresis treatment influences rheological markers and most likely improves metabolism in affected retinal areas, resulting not only in absorption of soft drusen but also reduction or complete disappearance of drusenoid retinal pigment epithelium detachments. However, the character of the treatment process has raised suspicion that there is a decrease not only in cholesterol but also in antioxidants, such as vitamin E and vitamin A. Methods. Twenty-three patients with the progressive dry form of age-related macular degeneration were each treated with 8 procedures of rheohaemapheresis. We measured levels of vitamin E (α-tocopherol), the vitamin E/cholesterol ratio in serum and lipoproteins (VLDL, LDL, HDL). Vitamin E in erythrocyte membrane and serum vitamin A (retinol) were also measured. These parameters were determined before and after rheohaemapheresis. Erythrocyte superoxide dismutase, erythrocyte glutathione peroxidase and serum malondialdehyde were analysed as markers of antioxidant activity and lipid peroxidation, respectively. Results. In serum, the VLDL and LDL fraction ratios of vitamin E/cholesterol increased significantly. Additionally, the HDL fraction ratio showed an increase but this was not statistically significant. The patients showed no clinical signs of vitamin E deficiency, and their serum concentrations of vitamin E did not differ from normal values. The results show that rheohaemapheresis in addition to causing a significant reduction in atherogenic LDL cholesterol, may have favourable additive anti-atherogenic effects due to a relative increase in the content of vitamin E in the lipoprotein fractions.

show abstract

“…Until now, there have been no effective pharmacological therapies for the dry form of AMD that have been documented by multicentre, randomised, double-blind studies 8,22 .…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Blood levels of antioxidants during age-related macular degeneration treatment by rheohaemapheresis

Aufartová¹,

Bláha²,

Kasalová³

et al. 2015

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

show abstract

“…This process is carried out in two main steps: blood cells are separated from plasma in the first step, while in the second step, LDL, liposomes, or other particles with diameter exceeding 30 nm are separated from plasma ( Fig. 3) (58,62,63). The filtration process operates in a continuous fashion and its efficacy depends on the volume of the treated plasma (53,59).…”

Section: Extracorporeal Apheresis Systemmentioning

confidence: 99%

Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients

Kubeček

Bláha

Díaz-García

et al. 2015

Acta Med. (Hradec Kralove, Czech Repub.)

View full text Add to dashboard Cite

3Summary: Ovarian cancer is the fifth most common malignancy in the world's female population and with the highest lethality index among gynecological tumors. The prognosis of metastatic disease is usually poor, especially in platinum-resistant cases. There are several options for the treatment of metastatic disease resistant to platinum derivates (e.g. paclitaxel, topotecan and pegylated liposomal doxorubicin), all of which are considered equipotent. Pegylated liposomal doxorubicin (PLD) is a liposomal form of the anthracycline antibiotic doxorubicin. It is characterized by more convenient pharmacokinetics and a different toxicity profile. Cardiotoxicity, the major adverse effect of conventional doxorubicin, is reduced in PLD as well as hematotoxicity, alopecia, nausea and vomiting. Skin toxicity and mucositis, however, emerge as serious issues since they represent dose and schedule-limiting toxicities. The pharmacokinetics of PLD (prolonged biological half-life and preferential distribution into tumor tissue) provide new possibilities to address these toxicity issues. The extracorporeal elimination of circulating liposomes after PLD saturation in the tumor tissue represents a novel and potent strategy to diminish drug toxicity. This article intends to review PLD characteristics and the importance of extracorporeal elimination to enhance treatment tolerance and benefits.

show abstract

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue

Schwartz

Padmanabhan

Aqui

et al. 2016

J of Clinical Apheresis

601

1,181

View full text Add to dashboard Cite

The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special Issue Writing Committee is charged with reviewing, updating, and categorizing indications for the evidence-based use of therapeutic apheresis in human disease. Since the 2007 JCA Special Issue (Fourth Edition), the Committee has incorporated systematic review and evidence-based approaches in the grading and categorization of apheresis indications. This Seventh Edition of the JCA Special Issue continues to maintain this methodology and rigor to make recommendations on the use of apheresis in a wide variety of diseases/conditions. The JCA Seventh Edition, like its predecessor, has consistently applied the category and grading system definitions in the fact sheets. The general layout and concept of a fact sheet that was used since the fourth edition has largely been maintained in this edition. Each fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis in a specific disease entity. The Seventh Edition discusses 87 fact sheets (14 new fact sheets since the Sixth Edition) for therapeutic apheresis diseases and medical conditions, with 179 indications, which are separately graded and categorized within the listed fact sheets. Several diseases that are Category IV which have been described in detail in previous editions and do not have significant new evidence since the last publication are summarized in a separate table. The Seventh Edition of the JCA Special Issue serves as a key resource that guides the utilization of therapeutic apheresis in the treatment of human disease. J. Clin. Apheresis 31:149-162, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

Rheohaemapheresis in the treatment of nonvascular age-related macular degeneration

Cited by 23 publications

References 18 publications

Blood levels of antioxidants during age-related macular degeneration treatment by rheohaemapheresis

Blood levels of antioxidants during age-related macular degeneration treatment by rheohaemapheresis

Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue

Contact Info

Product

Resources

About